An evaluation of tamoxifen dose escalation in advanced breast cancer

A. Goldhirsch; R. A. Joss; U. Leuenberger; F. Cavalli; H. J. Ryssel; K. W. Brunner

doi:10.1097/00000421-198210000-00006

An evaluation of tamoxifen dose escalation in advanced breast cancer

A. Goldhirsch, R. A. Joss, U. Leuenberger, F. Cavalli, H. J. Ryssel, K. W. Brunner

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18⁺ mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.

Original language	English (US)
Pages (from-to)	501-503
Number of pages	3
Journal	Unknown Journal
Volume	5
Issue number	5
DOIs	https://doi.org/10.1097/00000421-198210000-00006
State	Published - Jan 1 1982

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-198210000-00006

Cite this

@article{d5e3053d8e9a46a4a3612d17f45afbcb,

title = "An evaluation of tamoxifen dose escalation in advanced breast cancer",

abstract = "We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18+ mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.",

author = "A. Goldhirsch and Joss, {R. A.} and U. Leuenberger and F. Cavalli and Ryssel, {H. J.} and Brunner, {K. W.}",

year = "1982",

month = jan,

day = "1",

doi = "10.1097/00000421-198210000-00006",

language = "English (US)",

volume = "5",

pages = "501--503",

journal = "Unknown Journal",

issn = "0042-1215",

number = "5",

}

TY - JOUR

T1 - An evaluation of tamoxifen dose escalation in advanced breast cancer

AU - Goldhirsch, A.

AU - Joss, R. A.

AU - Leuenberger, U.

AU - Cavalli, F.

AU - Ryssel, H. J.

AU - Brunner, K. W.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18+ mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.

AB - We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18+ mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.

UR - http://www.scopus.com/inward/record.url?scp=0020403763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020403763&partnerID=8YFLogxK

U2 - 10.1097/00000421-198210000-00006

DO - 10.1097/00000421-198210000-00006

M3 - Article

C2 - 7180828

AN - SCOPUS:0020403763

SN - 0042-1215

VL - 5

SP - 501

EP - 503

JO - Unknown Journal

JF - Unknown Journal

IS - 5

ER -

An evaluation of tamoxifen dose escalation in advanced breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this